Our Mission Statement
This is Photoshop's version of Loremer Ipsn gravida nibh vel velit auctoregorie sam alquet.Aenean sollicitudin, lorem quis bibendum auci elit consequat ipsutis sem nibh id elit.
Follow Us
Who We Are – Transcell
page-template,page-template-full-width,page-template-full-width-php,page,page-id-6668,mkd-core-1.0,highrise-ver-1.0,,mkd-smooth-page-transitions,mkd-ajax,mkd-grid-1300,mkd-blog-installed,mkd-header-vertical,mkd-sticky-header-on-scroll-up,mkd-default-mobile-header,mkd-sticky-up-mobile-header,mkd-dropdown-slide-from-bottom,mkd-dark-header,mkd-full-width-wide-menu,mkd-search-dropdown,mkd-side-menu-slide-from-right,wpb-js-composer js-comp-ver-5.0.1,vc_responsive

Who We Are

Transcell Oncologics has dedicated team working on

  • Real time throughput screening of toolbox based novel complex compounds
  • Genomics of Indian cancer patients sourced cancer stem cells based platforms exposed to druggable molecules
  • Hunting for undruggable challenging targets in cancers for druggable molecules
  • Elucidating novel mechanistic pathways leading to known targets modulated by small molecules
  • Drug discovery from the insights of cancer genomics

As a stem cell based biotech company, we uniquely leverage our distinct insights from adult stem cells sourced from patients samples, donor samples, predictive stem cell technologies to discover the anti-cancer stem/cell properties, hunting for druggable molecules that selectively kill cancer stem cells. The data on human/patient based platforms/models, Genomics and Proteomics aid to advance our pipeline to clinical proof of concept and discovery of functional molecules. Access to all new nature inspired complex macrocyclic small molecules along with the wisdom derived from the stem cell technologies are our differentiating positioning in this space accelerating the process of drug discovery in Oncology.


The stem cells residing in tumour tissue are named cancer stem cells playing a key role in cancer relapses and metastasis. Transcell is into developing brain, breast, colon, prostate tumour-specific cancer stem cell harvesting techniques to productize the screens in hunting for small molecules that can kill cancer stem cells. The identified molecules with specifically targeted capacity will be further developed as drugs to cure solid tumours

The use of patient-derived cancer stem cell platforms is a realistic design in screening for molecules/drugs targeted killing assays. Salinomycin, Vacquinol-1 (2014) are the latest discoveries representing chemical libraries with targeted breast and brain cancer stem cells respectively killing properties aiding in designing/formulating drug of choice to cure otherwise relapsing cancers
There has been a reawakening of interest in the use of phenotypic screens in drug discovery as an alternative to target-focused approaches. As oncology is currently the most active therapeutic area in which target-focused approaches have been particularly prominent in the past, patient-derived cancer stem cell screens and phenotypic assays to discover cancer drugs is postulated in accelerated clinical developments. Therefore, technical and scalable advances that enable such mechanistically informed phenotypic models have the potential to empower phenotypic drug discovery in oncology
Testing toxicity and screening the particular property of new molecules/drugs to regenerate or differentiate into different lineages of the human body on the pluripotent stem cell-based platforms are unconventional catalysts in clinical development & drug discovery
From the medicinal chemistry vantage point, natural products and nature-inspired chemistry exemplify the abundant source of novel biologically relevant platforms for toolbox approach from which the druggable candidates for cancers are screened with selective functions